Renovo Lido5 Cream

Generic name: lidocaine, menthol and capsaicin
Dosage form: cream
Drug class:Topical anesthetics

Medically reviewed by Drugs.com. Last updated on May 23, 2022.

Disclaimer: This drug has not been found by FDA to be safe and effective, and this labeling has not been approved by FDA. For further information about unapproved drugs, click here.

DESCRIPTION

Disclaimer: The FDA has not evaluated this drug, and FDA has not approved this labeling.

Renovo Lido5 is a Lidocaine 5%, Menthol 3% and Capsaicin 0.05% cream which is a topical anesthetic and analgesic indicated for the relief of pain related to minor cuts, grazes and irritation

INDICATIONS AND USAGE

Renovo Lido5 is a topical anesthetic and analgesic indicated for the relief of pain related to minor cuts, grazes and irritations.

CONTRAINDICATIONS

Lidocaine is contraindicated in patients with a known history of hypersensitivity to local anesthetics of the amide type.

WARNINGS

For external use only.
Use only as directed.
Avoid contact with eyes and mucous membranes.
Do not cover with bandage.
Do not use on wounds or damaged skin.
Consult physician for children under 12.
Do not use if you are allergic to Menthol, Capsaicin or Lidocaine
Stop use and ask a doctor if conditions worsen, symptoms persist for more than 7 days or clear up and occur again within a few days or rash, itching or excessive skin irritation occurs.

KEEP OUT OF REACH OF CHILDREN.

Precautions

If irritation or sensitivity occurs or infection appears, discontinue use and institute appropriate therapy. Renovo Lido5 Cream should be used with caution in ill, elderly, debilitated patients and children who may be more sensitive to the systemic effects of lidocaine.

Carcinogenesis, Mutagenesis, and Impairment of Fertility:

Studies of lidocaine in animals to evaluate the carcinogenic and mutagenic potential of the effect on fertility have not been conducted.

USE IN PREGNANCY:

Teratogenic Effects; Pregnancy Category B.

Reproduction studies have been performed for lidocaine in rats at doses up to 6.6 times the human dose and have revealed no evidence of harm to the fetus caused by lidocaine. There are, however, no adequate and well-controlled studies in pregnant women. Animal reproduction studies are not always predictive of human response. General consideration should be given to this fact before administering lidocaine to women of childbearing potential, especially during early pregnancy when maximum organogenesis takes place.

NURSING MOTHERS: